Chong Kun Dang Pharmaceutical Corp.

KSE 185750.KS

Chong Kun Dang Pharmaceutical Corp. Free Cash Flow Yield on January 14, 2025: 23.08%

Chong Kun Dang Pharmaceutical Corp. Free Cash Flow Yield is 23.08% on January 14, 2025, a 29.92% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Chong Kun Dang Pharmaceutical Corp. 52-week high Free Cash Flow Yield is 25.33% on December 09, 2024, which is 9.76% above the current Free Cash Flow Yield.
Chong Kun Dang Pharmaceutical Corp. 52-week low Free Cash Flow Yield is 16.12% on September 03, 2024, which is -30.17% below the current Free Cash Flow Yield.
Chong Kun Dang Pharmaceutical Corp. average Free Cash Flow Yield for the last 52 weeks is 19.79%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

KSE: 185750.KS

Chong Kun Dang Pharmaceutical Corp.

CEO	Mr. Young-Joo Kim
IPO Date	Dec. 6, 2013
Location	South Korea
Headquarters	8, Chungjeong-ro
Employees	2,286
Sector	Health Care
Industries Pharmaceuticals Consumer Packaged Goods Drugstores & Retail Pharmacies

Description

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years